Can Amgen Balance Efficacy, Safety With KRAS/PD-1 Combination?

Data presented during the weekend at WCLC for Lumakras with Keytruda or Tecentriq raised questions about elevated liver toxicity and a lackluster response rate.

Amgen presented data for Lumakras at the World Conference on Lung Cancer • Source: Shutterstock

More from Immuno-oncology

More from Anticancer